DalCor Pharmaceuticals says it's still confident about its dal-GenE outcomes study of genetically selected patients treated with the cholesterol-modulating CETP inhibitor dalcetrapib, but the odds on its big gamble are arguably worsening after a new analysis of Merck & Co. Inc.'s REVEAL outcomes study of anacetrapib did not support the hypothesis.
A retrospective analysis of data from Merck's massive REVEAL outcomes study of its CETP inhibitor anacetrapib, presented at the American College of Cardiology (ACC) annual meeting on March 18, did not show a trend for a benefit
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?